4/15
12:10 pm
cue
Here's Why Cue Biopharma (CUE) Is a Great 'Buy the Bottom' Stock Now [Yahoo! Finance]
Medium
Report
Here's Why Cue Biopharma (CUE) Is a Great 'Buy the Bottom' Stock Now [Yahoo! Finance]
4/9
09:08 am
cue
Cue Biopharma, Inc. (NASDAQ: CUE) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $8.00 price target on the stock.
Medium
Report
Cue Biopharma, Inc. (NASDAQ: CUE) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $8.00 price target on the stock.
4/9
08:44 am
cue
Cue Biopharma, Inc. (NASDAQ: CUE) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $10.00 price target on the stock.
Low
Report
Cue Biopharma, Inc. (NASDAQ: CUE) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $10.00 price target on the stock.
4/8
04:11 pm
cue
Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights [Yahoo! Finance]
Medium
Report
Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights [Yahoo! Finance]
4/8
04:05 pm
cue
Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights
Medium
Report
Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights
4/3
12:11 pm
cue
Cue Biopharma, Inc. (NASDAQ: CUE) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $8.00 price target on the stock.
Low
Report
Cue Biopharma, Inc. (NASDAQ: CUE) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $8.00 price target on the stock.
4/2
08:24 am
cue
Cue Biopharma to Host Business Update Call and Webcast [Yahoo! Finance]
Medium
Report
Cue Biopharma to Host Business Update Call and Webcast [Yahoo! Finance]
4/2
08:00 am
cue
Cue Biopharma to Host Business Update Call and Webcast
Medium
Report
Cue Biopharma to Host Business Update Call and Webcast
3/13
07:31 am
cue
Cue Biopharma, Inc. (NASDAQ: CUE) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $6.00 price target on the stock.
High
Report
Cue Biopharma, Inc. (NASDAQ: CUE) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $6.00 price target on the stock.
2/29
10:12 am
cue
Cue Biopharma's Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium [Yahoo! Finance]
Low
Report
Cue Biopharma's Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium [Yahoo! Finance]
2/29
10:00 am
cue
Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium
Low
Report
Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium
2/6
08:13 am
cue
Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
High
Report
Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
2/6
08:00 am
cue
Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Medium
Report
Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference